All News

David Liew Tweet
drdavidliew
STAR-RA, CV risk large insurance datax3 tofa vs TNFi all comers: HR 1.01 (0.83-1.23) one CV RF + any MTX: HR 1.24 (0.90-1.69) prev CVD: HR 1.27 (0.95-1.70) not sig but surely okay to say baseline CV risk + tofa makes me a little nervous? @SeoyoungCKim #ACR21 ABST1939 @RheumNow https://t.co/LmmL5zgv9u
Aurelie Najm Tweet
AurelieRheumo
Another study linking long term GC and CV risk in RA! Medicare data >65yo 130000+ pts 1-year incidence CV ⬆️ as follows: 📍Dose ≤5mg 1.4% 📍Dose 5-10mg 1.7% 📍Dose >10mg 1.9% Not replicated in younger pts (Optum data) #ACR21 #Abst1915 @RheumNow https://t.co/DLXdfvfiBW
Mrinalini Dey Tweet
DrMiniDey
Can we predict who will develop #RA-ILD? Perhaps anti-MAA is the answer! #ACR21 Abs#1916 👉🏼⬆️anti-MAA antibody assoc with incident ILD risk 👉🏼Associations are antigen & isotype dependent 👉🏼Antibody measurement may be useful to risk stratify for RA-ILD @RheumNow https://t.co/nC0OkuWtGU
Mrinalini Dey Tweet
DrMiniDey
#ACR21 Abs#1915 👉🏼Chronic steroid use in older adults on stable DMARD therapy assoc w/ ⬆️CV risk 👉🏼Risk even present among older adults receiving low dose ≤5mg/day 👉🏼Larger studies needed in younger healthier adults @RheumNow https://t.co/Lsj5YBz7IG
sheila Tweet
RHEUMarampa
Post hoc analysis of pooled data from 19 clin trials on SEC & CV risk & systemic #inflammation in PsO, PsA, AS 📌Traditional CV parameters remained stable on all SEC treated grps 📌SEC sig. ⬇hsCRP & NLR @RheumNow #ACR21 abs1835 https://t.co/iCaGFbXNXn
Janet Pope Tweet
Janetbirdope
Advantages of treat to target (of serum urate) beyond less gout flares? Maybe equal to ⬇️MACE events - I hope in long term less MACE due to less ⬆️CRP w flares. Modelling observational study abst#L06 #ACR21 #ACRBest @RheumNow below is comparative safety T2T better than usual care https://t.co/95M6lNX416
David Liew Tweet
drdavidliew
I don't know much about antifibrotics in RA-ILD, but these data emphasise that HRCT pattern matters My simple mind, for any disease: multiple subtypes with different trajectories➡️likely to be differing responses to Rx TRAIL1: pirfenidone in RA-ILD #ACR21 ABSTL10 @RheumNow https://t.co/v7HCO0ZBe1
Richard Conway Tweet
RichardPAConway
Comparative effects of abatacept in RA-ILD with UIP/NSIP. Appears equally effective in stabilising FVC, DLCO, and HRCT findings in both. Abstr#1683 #ACR21 @RheumNow https://t.co/l0Ia1D9c56
Aurelie Najm Tweet
AurelieRheumo
☄️Late breakingTRAIL1 RCT Pirfenidone on RA-ILD. ✨Primary outcome on incidence of decline of >10% FVC or death not met 11% PIR vs. 15% PBO OR=0.67 p=0.48 BUT ✨underpowered ✨reduces decline in FVC(ml) over 52wk (-66 vs. -146, p=0.0082) ✨safety ok #ACR21 #AbstL10 @RheumNow https://t.co/IxYDE3lN1s
sheila Tweet
RHEUMarampa
In this study: 💊No correlation bet QTc interval & whole blood HCQ level regardless of dose, CKD or abnormal TTEs in #lupus pts 💊+correlation bet QTci & HCQ levels in pts w/ QTc prolonging drugs but not >456ms Reassuring, dispels concern on HCQ use @RheumNow #ACR21 abs1743 https://t.co/kpASRAXJB1
David Liew Tweet
drdavidliew
Will a FDA black box warning change your JAKi practice? In May 2019, the EMA put out a warning about VTE with tofacitinib. In this French cohort, did it change the kind of pts they initiated on JAKi? no, not it did not😊 A window into the US future? #ACR21 ABST1245 @RheumNow https://t.co/QI95E1gepg
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×